HomeCompanyTechnologyPipelineInvestors & MediaContact

Our TCR-T cells are engineered to target virus-derived peptides presented on MHC class I on cell surface.

I. Virus-infected cells

Upon virus infection, viral proteins are expressed in the infected cells. These viral proteins are degraded into viral peptides and assembled with MHC class I to be presented onto the cell surface. These peptide-MHC I complexes on the infected cell surface are recognized by cytotoxic T cells, leading to the release of cytokines and triggering antiviral responses.

II. Virus-related cancer cells

Upon virus infection, viral proteins are expressed in the infected cells. These viral proteins are degraded into viral peptides and assembled with MHC class I to be presented onto the cell surface. These peptide-MHC I complexes on the infected cell surface are recognized by cytotoxic T cells, leading to the release of cytokines and triggering antiviral responses.

Clinical Application

1. The patient undergoes leukapheresis to isolate white blood cells.

2. T cells from the patient are expanded and activated in Lion TCR’s GMP cell production center.

3. Genetic material encoding our virus- or cancer-targeting TCR are introduced into the activated T cells by viral transduction or electroporation.

4. The patient’s T cells now express the relevant TCR that target virus-infected or virus-related cancer cells.

5. Following phenotypic and functional validation, the TCR engineered T cells are infused back to the patient.

Publications

P065 Phase 1 study of autologous hepatitis B virus (HBV) specific T cell receptor (TCR) T cells, LioCyx M in unresectable HBV related hepatocellular carcinoma (HCC)

Wang et al. EASL Digital Liver Cancer Summit (2021)

O07 Immunological alterations induced by HBV-TCR T cell immunotherapy associates with treatment response of primary HBV related-HCC

Tan et al. EASL Digital Liver Cancer Summit (2021)

Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients

Hafezi et al. Hepatology (2020)

Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation

Chen W et al. Journal for ImmunoTherapy of Cancer (2020)

Use of LioCyx-M, autologous hepatitis B virus (HBV)-Specific T cell receptor (TCR) T-cells, in advanced HBV-related hepatocellular carcinoma (HCC)

Wang FS et al. Journal for ImmunoTherapy of Cancer (2020)

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy

Tan AT et al. Gastroenterology (2019)

TCRs in Development

Our library of TCRs recognizes viral peptides expressed on MHC Class I restricted for the Asian population.

We are actively extending our proprietary TCR therapy platform to target more viruses, particularly those prevalent in Asia, for example, HBV, EBV and CMV.

pipeline